Pyrotinib alone or in combination with docetaxel in refractory HER2‐positive gastric cancer: A dose‐escalation phase I study

Pyrotinib alone or in combination with docetaxel in refractory HER2‐positive gastric cancer: A dose‐escalation phase I study

Abstract Aim Pyrotinib (an irreversible pan‐ErbB small‐molecular tyrosine kinase inhibitor) was approved in human epidermal growth factor receptor 2 (HER2)‐positive breast cancer and showed great antitumor activity in preclinical studies of gastric cancer (GC). This study was first designed to prosp...

Full description

Bibliographic Details
Main Authors: Dan Liu, Furong Kou, Jifang Gong, Zhiqiang Wang, Xiaotian Zhang, Jian Li, Yan Li, Jie Li, Jun Zhou, Ming Lu, Xicheng Wang, Zhihao Lu, Yanshuo Cao, Jianjun Zou, Xiaoyu Zhu, Ruihua Xu, Lin Shen
Format: Article
Language:English
Published: Wiley 2023-05-01
Series:Cancer Medicine
Subjects:
docetaxel
gastric cancer
HER2
phase I study
pyrotinib
Online Access:https://doi.org/10.1002/cam4.5830

Internet

https://doi.org/10.1002/cam4.5830

Similar Items